 |
138 Diseases |  |
94 Trials |
|
94 Trials |  |
2090 News |  |
| «12...1819202122232425262728...3233» |
- | Erleada (apalutamide) / J&J
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Sep 16, 2019
P2, N=9, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=33 --> 9 | Trial completion date: Aug 2024 --> Dec 2019 | Trial primary completion date: Aug 2020 --> May 2019
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda, Orilissa (elagolix) / AbbVie
just remember they are the folks who got a court order to shut down the true nature of Lupron, and made claims on elagolix that are. not accurate, as well as claiming relief in deep disease with it which is not accurate (Twitter) - Sep 15, 2019
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Adverse events: I am particularly concerned about Abbvie's relationship with the researchers, when the company has a history of hiding serious side effects from Lupron with a court order. Then having consultants conduct studies, write papers then edit the papers, where is the accountability (Twitter) - Sep 15, 2019
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Yup yup and yup stampede is bigger than I o lupron abi 6 months 50 guy or brachytherapy done (Twitter) - Sep 15, 2019
- | Ibrance (palbociclib) / Pfizer
Trial completion, Metastases: A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer (clinicaltrials.gov) - Sep 12, 2019
P2, N=72, Completed, Sponsor: University of Michigan Rogel Cancer Center
Recruiting --> Active, not recruiting | N=33 --> 9 | Trial completion date: Aug 2024 --> Dec 2019 | Trial primary completion date: Aug 2020 --> May 2019 Active, not recruiting --> Completed
- | leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer (clinicaltrials.gov) - Sep 11, 2019
P1, N=26, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed Trial completion date: Aug 2019 --> Aug 2021 | Trial primary completion date: Aug 2019 --> Aug 2021
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date: Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer (clinicaltrials.gov) - Sep 9, 2019
P2, N=9, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Aug 2019 --> Aug 2021 | Trial primary completion date: Aug 2019 --> Aug 2021 Trial completion date: Apr 2019 --> Dec 2019 | Trial primary completion date: Apr 2019 --> Dec 2019
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical: Prostate ? Maybe with neo adjuvant abi lupron? Not genetically based and won’t happen. Gbm ha! For binary decisions treat no treat might work or dose escalation for modestly curable tumors. This is a mis adventure (Twitter) - Aug 28, 2019
- | Estrace (estradiol) / AbbVie
New P2 trial: Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model (clinicaltrials.gov) - Aug 8, 2019
P2, N=30, Not yet recruiting, Sponsor: University of North Carolina, Chapel Hill
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda, Orilissa (elagolix) / AbbVie
Clinical: #Transparency #WomensHealthcare #WarOnWomen #Lupron #Orilissa #Abbvie @Abbvie @lizzieohreally @dianafalzone #MeToo (Twitter) - Aug 7, 2019
- | letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Aug 7, 2019
P2, N=84, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Apr 2019 --> Dec 2019 | Trial primary completion date: Apr 2019 --> Dec 2019 Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Jul 2020
- | leuprolide acetate for depot suspension / Generic mfg., anastrozole / Generic mfg., testosterone gel / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Regulation of Cortisol Metabolism and Fat Patterning (clinicaltrials.gov) - Aug 7, 2019
P=N/A, N=140, Active, not recruiting, Sponsor: Oregon Health and Science University
Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Jul 2020 Completed --> Active, not recruiting | Trial completion date: Sep 2009 --> Sep 2020 | Trial primary completion date: Mar 2009 --> Mar 2020
- | docetaxel / Generic mfg.
Trial completion: Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer (clinicaltrials.gov) - Jul 24, 2019
P1/2, N=27, Completed, Sponsor: University of Kansas Medical Center
Completed --> Active, not recruiting | Trial completion date: Sep 2009 --> Sep 2020 | Trial primary completion date: Mar 2009 --> Mar 2020 Active, not recruiting --> Completed
- | Vesanoid (tretinoin) / Roche
Trial primary completion date: A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment (clinicaltrials.gov) - Jul 22, 2019
P2, N=20, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed Trial primary completion date: Oct 2019 --> Feb 2021
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
What about lupron abi or lupron enzi plus ebrt plus brachytherapy for Gleason 9 or 10? (Twitter) - Jul 20, 2019
- | Piqray (alpelisib) / Novartis
Trial completion date, Trial primary completion date, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Jul 9, 2019
P2, N=340, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2019 --> Feb 2021 Trial completion date: Sep 2020 --> Nov 2021 | Trial primary completion date: Apr 2020 --> Nov 2020
- | Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open: Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis (clinicaltrials.gov) - Jun 30, 2019
P3, N=320, Recruiting, Sponsor: ASKA Pharmaceutical Co., Ltd.
Trial completion date: Sep 2020 --> Nov 2021 | Trial primary completion date: Apr 2020 --> Nov 2020 Not yet recruiting --> Recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment closed, Enrollment change: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Jun 27, 2019
P2, N=19, Active, not recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=56 --> 19
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion: Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) (clinicaltrials.gov) - Jun 26, 2019
P2, N=38, Completed, Sponsor: Duke University
Recruiting --> Active, not recruiting | N=56 --> 19 Active, not recruiting --> Completed
- | leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
New trial: Defining Recurrent Disease With Axumin (clinicaltrials.gov) - Jun 24, 2019
P, N=20, Recruiting, Sponsor: Cancer Center of Irvine
- | everolimus / Generic mfg.
Enrollment closed: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Jun 24, 2019
P3, N=1900, Active, not recruiting, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
Trial completion date, Trial primary completion date: A Registry for Patients Treated on the Clinical Trial TAX 3503 (clinicaltrials.gov) - Jun 14, 2019
P3, N=52, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Mar 2020
- || Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date: c15-164: AASUR in High Risk Prostate Cancer (clinicaltrials.gov) - Jun 14, 2019
P2, N=58, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Mar 2020 Trial completion date: May 2019 --> May 2020 | Trial primary completion date: May 2019 --> May 2020
- || Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date: Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer (clinicaltrials.gov) - Jun 5, 2019
P2, N=66, Not yet recruiting, Sponsor: Robert J Amato
Trial completion date: May 2019 --> May 2020 | Trial primary completion date: May 2019 --> May 2020 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
- | leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg., docetaxel / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: oligo-mets: A Study of Definitive Therapy to Treat Prostate Cancer (clinicaltrials.gov) - Jun 5, 2019
P2, N=33, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024 Trial completion date: Mar 2021 --> Apr 2024 | Trial primary completion date: Mar 2019 --> Apr 2022
- Yselty (linzagolix) / Kissei, Theramex, Syneos Health
Trial completion: Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis (clinicaltrials.gov) - Jun 4, 2019
P2, N=0, Completed, Sponsor: Kissei Pharmaceutical Co., Ltd.
Trial completion date: Mar 2021 --> Apr 2024 | Trial primary completion date: Mar 2019 --> Apr 2022 Active, not recruiting --> Completed
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
@ZEROCancer out getting it done on the bike despite the Lupron shots (Twitter) - Jun 1, 2019
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, HEOR, Combination therapy: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - May 30, 2019
P2, N=257, Active, not recruiting, Sponsor: Palleos Healthcare GmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | leuprolide acetate for depot suspension / Generic mfg., megestrol / Generic mfg.
New P4 trial: Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine (clinicaltrials.gov) - May 28, 2019
P4, N=164, Not yet recruiting, Sponsor: Children's Hospital of Fudan University
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - May 24, 2019
P2, N=56, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2019 --> Oct 2019
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial termination: DUALTRIGGER: Study of Dual Trigger Ovulation in Oocyte Donors (clinicaltrials.gov) - May 22, 2019
P4, N=26, Terminated, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Mar 2019 --> Oct 2019 N=180 --> 26 | Recruiting --> Terminated; Unable to complete accrual
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Lupron only gave me severe hot flashes.😡 It did NOT shrink my fibroid. Not even a centimeter! And to think, Lupron only increased my anxiety as fibroid treatment was still in its early stages. No Lupron for me! (Twitter) - May 20, 2019
- || Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial, Metastases: PRIME-CUT: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer (clinicaltrials.gov) - May 14, 2019
P2, N=20, Recruiting, Sponsor: Mark Stein
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Or abi lupron but shorter (Twitter) - May 13, 2019
- |||| Kisqali (ribociclib) / Novartis
New P2 trial, Combination therapy, Metastases: FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (clinicaltrials.gov) - May 8, 2019
P2, N=194, Recruiting, Sponsor: Fondazione Sandro Pitigliani
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: PEER: Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - May 3, 2019
P1/2, N=25, Recruiting, Sponsor: National Taiwan University Hospital
N=180 --> 26 | Recruiting --> Terminated; Unable to complete accrual Not yet recruiting --> Recruiting
- |||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical: education may help, but this drug will not, it is lupron repackaged, initially they widely touted it as a miracle, then toned down still marketing for DIE, in their own studies which they quit following 100% of patient still had pain on lupron. they hid true nature in courtorder (Twitter) - May 2, 2019
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical, Adverse events: But we also teach patients that the new oral drug is a disaster when it comes to cost, effectiveness, and side effects, principal investigators who contacted me agreed with all of that noting it has all of the same problems lupron does (Twitter) - May 1, 2019
- | Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis (clinicaltrials.gov) - Apr 29, 2019
P3, N=320, Not yet recruiting, Sponsor: ASKA Pharmaceutical Co., Ltd.
- | Lupron Depot (leuprorelin depot) / AbbVie, Takeda, Eligard (leuprolide acetate) / TOLMAR, Astellas, Sanofi
Clinical, Journal: Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression. (Pubmed Central) - Apr 26, 2019
Not yet recruiting --> Recruiting Women with suspected endometriosis and aberrant endometrial BCL6 expression have worse reproductive outcomes following embryo transfer, including a high miscarriage rate, poor IR, and low LBR and CPR compared to cycles pre-treated with medical and surgical management.
- || leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: CRONOS II: Evaluation of Diet and Exercise in Prostate Cancer Patients (clinicaltrials.gov) - Apr 24, 2019
P=N/A, N=1300, Recruiting, Sponsor: AbbVie
Women with suspected endometriosis and aberrant endometrial BCL6 expression have worse reproductive outcomes following embryo transfer, including a high miscarriage rate, poor IR, and low LBR and CPR compared to cycles pre-treated with medical and surgical management. Trial completion date: Aug 2022 ->Jul 2021 | Trial primary completion date: Aug 2022 --> Jul 2021
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Combination therapy: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer (clinicaltrials.gov) - Apr 20, 2019
P1, N=25, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Trial completion date: Aug 2022 ->Jul 2021 | Trial primary completion date: Aug 2022 --> Jul 2021 Trial completion date: Jan 2019 --> Jan 2020
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date: Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) (clinicaltrials.gov) - Apr 19, 2019
P2, N=38, Active, not recruiting, Sponsor: Duke University
Trial completion date: Jan 2019 --> Jan 2020 Trial completion date: Mar 2019 --> Jun 2019
- | Livial (tibolone) / Organon
Trial completion date, Trial primary completion date: Psychological Impact of Amenorrhea in Women With Endometriosis (clinicaltrials.gov) - Apr 19, 2019
P4, N=50, Not yet recruiting, Sponsor: University of Cagliari
Trial completion date: Mar 2019 --> Jun 2019 Trial completion date: Mar 2017 --> May 2020 | Trial primary completion date: Dec 2016 --> Dec 2019
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, HEOR, Combination therapy: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - Apr 18, 2019
P2, N=257, Recruiting, Sponsor: Palleos Healthcare GmbH
Trial completion date: Mar 2017 --> May 2020 | Trial primary completion date: Dec 2016 --> Dec 2019 Trial completion date: Nov 2024 --> Feb 2024
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial initiation date, Trial withdrawal: GRAET: GnRH Agonist at Embryo Transfer: IVF Outcomes (clinicaltrials.gov) - Apr 16, 2019
P3, N=0, Withdrawn, Sponsor: Maimonides Medical Center
Trial completion date: Nov 2024 --> Feb 2024 Initiation date: Nov 2018 --> Apr 2019 | Not yet recruiting --> Withdrawn | N=442 --> 0
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
I had Casodex for 3 weeks and then Lupron for a year. All of it was covered by the government. (Twitter) - Apr 15, 2019
- | Ibrance (palbociclib) / Pfizer
Enrollment closed, Combination therapy, Metastases: A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC (clinicaltrials.gov) - Apr 8, 2019
P2, N=182, Active, not recruiting, Sponsor: Samsung Medical Center
Initiation date: Nov 2018 --> Apr 2019 | Not yet recruiting --> Withdrawn | N=442 --> 0 Recruiting --> Active, not recruiting
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Also do not know if you would want to follow labs on these guys. T replacement is not universal dosing, there are 7-10 different ways to replace and clomid an option. Just saying it’s not like starting lupron. It’s an art that takes time in the office, staff, lab etc. (Twitter) - Apr 6, 2019
- | New P2 trial, Surgery: PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate (clinicaltrials.gov) - Apr 3, 2019
P2, N=122, Not yet recruiting, Sponsor: Seoul National University Hospital